Orthocell Posts Record U.S. Remplir Sales in October 2026
Australian medtech Orthocell hit its highest U.S. monthly sales for its Remplir nerve wrap since the product launched, moving 92 units in October 2026.
Orthocell Ltd, the Australian medical device manufacturer, recorded its strongest month of U.S. sales for its Remplir nerve wrap in October 2026, shipping 92 units in a single month — a milestone the company described as its best performance since the product's commercial launch.
Remplir is an FDA-cleared collagen nerve wrap engineered to support the repair and protection of peripheral nerves. Developed and produced in Australia, the device is positioning itself as a category leader in key international markets, according to the company.
Read more Bahrain Awards Golden Licenses to Four Projects Worth $3.89B →
The October result signals growing clinical adoption of a product that competes in the peripheral nerve repair segment, a niche but expanding corner of the surgical device market. Consistent month-over-month traction in the U.S. — the world's largest medical device market — is typically viewed as a meaningful indicator of commercial viability for emerging medtech firms.
Orthocell's ability to manufacture an FDA-cleared device from Australia and drive record sales volumes in the U.S. underscores a broader trend of international medtech companies gaining footholds in American hospital and surgical center supply chains. The 92-unit October figure, while modest in absolute terms, represents a qualitative inflection point for the company's North American commercial strategy.
Continue reading at All Financial Services & Investing.
